This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lin, C.-Y. Articles by Butler, P. C. Search for Related Content PubMed PubMed Citation Articles by Lin, C.-Y. Articles by Butler, P. C. Related Collections Diabetes and Insulin

Activation of Peroxisome Proliferator-Activated Receptor- by Rosiglitazone Protects Human Islet Cells against Human Islet Amyloid Polypeptide Toxicity by a Phosphatidylinositol 3'-Kinase-Dependent Pathway

Larry Hillblom Islet Research Center, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095-7073

Address all correspondence and requests for reprints to: Dr. Peter C. Butler, Larry Hillblom Islet Research Center, Division of Endocrinology, David Geffen School of Medicine at University of California Los Angeles, 900A Weyburn Place North, Los Angeles, California 90095-7073. E-mail: pbutler{at}mednet.ucla.edu.

Background: Type 2 diabetes mellitus (T2DM) is characterized by a deficit in ß-cell mass, increased ß-cell apoptosis, and islet amyloid derived from islet amyloid polypeptide (IAPP). Human IAPP (h-IAPP) applied to ß-cells forms toxic oligomers that induce apoptosis. Thiazolidinediones, ligands of peroxisome proliferator-activated receptor- (PPAR-), can delay the onset of T2DM.

Objective: We questioned whether activation of endogenous PPAR- in human islets by rosiglitazone (RSG) inhibits h-IAPP-induced islet cell death and, if so, by which mechanism.

Methods and Results: Vehicle or h-IAPP was applied to human islets with or without RSG (10 and 50 µM) for 48 h. A 2-fold increase in the number of terminal deoxynucleotidyl transferase-mediated deoxy-UTP nick end labeling-positive nuclei was detected in h-IAPP-treated human islets (P < 0.001). RSG (10 and 50 µM) prevented h-IAPP-induced apoptosis in human islets (P < 0.001). Thioflavin T binding assays confirmed that this effect was not mediated by interference with h-IAPP oligomerization. Expression of dominant negative PPAR- in human islets prevented the protective effect of RSG. RSG activation of PPAR- resulted in downstream activation of the serine/threonine protein kinase Akt, an outcome that was inhibited by a specific phosphatidylinositol 3-kinase inhibitor, which ablated RSG protection against h-IAPP-induced islet cell apoptosis.

Conclusion: We conclude that in human islets, activation of PPAR- inhibits h-IAPP-induced islet cell apoptosis, and this action is at least in part mediated through activation of the phosphatidylinositol 3'-kinase-Akt cascade. If this action is present in vivo, then thiazolidinediones have the potential to decrease ß-cell apoptosis in T2DM and reduce loss of ß-cell mass.

This article has been cited by other articles:

				M. M. Sachdeva and D. A. Stoffers Minireview: Meeting the Demand for Insulin: Molecular Mechanisms of Adaptive Postnatal ss-Cell Mass Expansion Mol. Endocrinol., June 1, 2009; 23(6): 747 - 758. [Abstract] [Full Text] [PDF]

				R. A. DeFronzo From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus Diabetes, April 1, 2009; 58(4): 773 - 795. [Full Text] [PDF]

				D. Gupta, T. L. Jetton, R. M. Mortensen, S. Z. Duan, M. Peshavaria, and J. L. Leahy In Vivo and in Vitro Studies of a Functional Peroxisome Proliferator-activated Receptor {gamma} Response Element in the Mouse pdx-1 Promoter J. Biol. Chem., November 21, 2008; 283(47): 32462 - 32470. [Abstract] [Full Text] [PDF]

				E. Tozzo, R. Ponticiello, J. Swartz, D. Farrelly, R. Zebo, G. Welzel, D. Egan, L. Kunselman, A. Peters, L. Gu, et al. The Dual Peroxisome Proliferator-Activated Receptor {alpha}/{gamma} Activator Muraglitazar Prevents the Natural Progression of Diabetes in db/db Mice J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 107 - 115. [Abstract] [Full Text] [PDF]

				A. M. Sharma and B. Staels Peroxisome Proliferator-Activated Receptor {gamma} and Adipose Tissue--Understanding Obesity-Related Changes in Regulation of Lipid and Glucose Metabolism J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 386 - 395. [Abstract] [Full Text] [PDF]

				J. A. Moibi, D. Gupta, T. L. Jetton, M. Peshavaria, R. Desai, and J. L. Leahy Peroxisome Proliferator-Activated Receptor-{gamma} Regulates Expression of PDX-1 and NKX6.1 in INS-1 Cells Diabetes, January 1, 2007; 56(1): 88 - 95. [Abstract] [Full Text] [PDF]

				J. J. Meier, R. Kayed, C.-Y. Lin, T. Gurlo, L. Haataja, S. Jayasinghe, R. Langen, C. G. Glabe, and P. C. Butler Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1317 - E1324. [Abstract] [Full Text] [PDF]